- Home
- KITT vs RNAZ Comparison
KITT vs RNAZ Comparison
Compare KITT & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KITT | RNAZ |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KITT | RNAZ |
|---|---|---|
| Price | $0.90 | $7.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | ★ 7.1M | 132.7K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,688,840.00 | N/A |
| Revenue This Year | $2,936.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 95.38 | N/A |
| 52 Week Low | $0.69 | $6.08 |
| 52 Week High | $54.36 | $468.44 |
Technical Indicators
Market Signals| Indicator | KITT | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 46.93 |
| Support Level | $0.69 | $6.50 |
| Resistance Level | $1.10 | $8.20 |
| Average True Range (ATR) | 0.10 | 0.88 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 50.94 | 53.76 |
Price Performance
Historical ComparisonAbout KITT Nauticus Robotics Inc.
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.